Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer ends breast cancer drug trials

Pfizer ends breast cancer drug trials

16th April 2015

Pfizer has announced it is bringing its trials involving the breast cancer drug Ibrance to an end, in line with pharmaceutical industry regulator rules.

The company was conducting phase III trials to test the effectiveness of the drug in extending life expectancy in females with the disease and had received regulatory approval from the US Food and Drug Administration for its development.

However, despite positive results being achieved in the trials and evidence suggesting that Ibrance could help to prolong the lives of breast cancer patients, time has been called on the investigations because it met all of its targets for progression-free survival.

Dr Mace Rothenberg, senior vice-president of clinical development and medical affairs and chief medical officer of Pfizer's oncology department, commented: "We're gratified to be able to stop the trial early and are engaging in discussions with health authorities regarding a regulatory path forward."

Pfizer will be presenting a full set of results relating to Ibrance at the American Society of Clinical Oncology's annual meeting later this year.ADNFCR-8000103-ID-801783806-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.